The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants
Open accessAbstract
BACKGROUND: Corticosteroids have been used late in the neonatal period to treat chronic lung disease (CLD) in preterm babies, and early to try to prevent it. CLD is likely to be the result of persisting inflammation in the lung and the use of powerful anti-inflammatory drugs like dexamethasone has some rationale. Early use tends to be associated with increased adverse effects so that studies of moderately early treatment (7-14 days postnatal) might have the dual benefits of fewer side effects and onset of action before chronic inflammation is established. OBJECTIVES: To determine if moderately early (7-14 days) postnatal corticosteroid treatment vs control (placebo or nothing) is of benefit in the prevention and/or treatment of early chronic lung disease in the preterm infant. SEARCH STRATEGY: Randomised controlled trials of postnatal corticosteroid therapy were sought from the Oxford Database of Perinatal Trials, Cochrane Database of Controlled Trials, MEDLINE (1966 - October 2002), hand searching paediatric and perinatal journals, examining previous review articles and information received from practicing neonatologists. Authors of all studies were contacted, where possible, to confirm details of reported follow-up studies, or to obtain any information about long-term follow-up where none had been reported. SELECTION CRITERIA: Randomised controlled trials of postnatal corticosteroid treatment from 7-14 days of birth in high risk preterm infants were selected for this review. DATA COLLECTION AND ANALYSIS: Data regarding clinical outcomes including mortality, CLD (including late rescue with corticosteroids, or need for home oxygen therapy), death or CLD, failure to extubate, complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, hypertrophic cardiomyopathy, pneumothorax, severe intraventricular haemorrhage (IVH), necrotizing enterocolitis (NEC), gastrointestinal bleeding, and severe retinopathy of prematurity (ROP)), and long term outcome (including blindness, deafness, cerebral palsy and major neurosensory disability), were abstracted and analysed using RevMan 4.1. MAIN RESULTS: Seven studies enrolling a total of 669 participants were eligible for inclusion in this review. Moderately early steroid treatment (vs placebo or nothing) reduced mortality by 28 days, chronic lung disease at 28 days and 36 weeks, and death or chronic lung disease at 28 days or 36 weeks. Earlier extubation was facilitated. There was no significant effect on the rates of pneumothorax, severe ROP, or NEC. Adverse effects included hypertension, hyperglycaemia, gastrointestinal bleeding, hypertrophic cardiomyopathy and infection. Steroid-treated infants were less likely to need late rescue with dexamethasone. There were limited data from four studies of long term follow-up; these did not show evidence of an increase in adverse neurological outcomes. REVIEWER'S CONCLUSIONS: Moderately early corticosteroid therapy (started at 7-14 days) reduces neonatal mortality and CLD, but at the cost of important short term adverse effects. Limited evidence concerning long term effects is provided by the trials included in this review. The methodological quality of the studies determining the long-term outcome is limited in some cases, the children have been assessed predominantly before school age, and no study has been sufficiently powered to detect important adverse long-term neurosensory outcomes. Therefore, given the risk:benefit ratio of short-term effects and the limited long-term follow-up data, it seems appropriate to reserve moderately early corticosteroid treatment to infants who cannot be weaned from mechanical ventilation and to minimise the dose and duration of any course of therapy. More research is urgently needed, including long term follow-up of survivors included in previous and any future trials, before the benefits and risks of postnatal steroid treatment, including initiation at 7-14 days, can be reliably assessed (See DART study; Doyle 2000a).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
A Controlled Trial of Dexamethasone in Preterm Infants at High Risk for Bronchopulmonary Dysplasia
Cummings, J. J., D'Eugenio, D. B., & Gross, S. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906083202301 · Cited by 483
CONTROLLED TRIAL OF DEXAMETHASONE THERAPY IN INFANTS WITH BRONCHOPULMONARY DYSPLASIA
Mammel, M., Johnson, D., Green, T., & Thompson, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92139-6 · Cited by 307
Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants
Halliday, H., Ehrenkranz, R., & Doyle, L. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001145 · Cited by 218
Self-citationLate (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants
Halliday, H. L., Ehrenkranz, R. A., & Doyle, L. W. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001145.pub2 · Cited by 205
Self-citationA Multicenter Trial of Two Dexamethasone Regimens in Ventilator-Dependent Premature Infants
Papile, L.-A., Tyson, J. E., Stoll, B. J., Wright, L. L., Donovan, E. F., Bauer, C. R., Krause-Steinrauf, H., Verter, J., Korones, S. B., Lemons, J. A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804163381604 · Cited by 172
Self-citationBhuta, T., & Ohlsson, A. (1998) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.79.1.f26 · Cited by 145
Groneck, P., Reuss, D., Götze‐Speer, B., & Speer, C. P. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(09)90024-5 · Cited by 145
Halliday, H. L., & Sweet, D. G. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000500 · Cited by 127
Self-citationDexamethasone Therapy Increases Infection in Very Low Birth Weight Infants
Stoll, B. J., Temprosa, M. G., Tyson, J. E., Papile, L. A., Wright, L. L., Bauer, C. R., Donovan, E. F., Korones, S. B., Lemons, J. A., Fanaroff, A. A., et al. (1999) · PEDIATRICS · doi:10.1542/peds.104.5.e63 · Cited by 123
Self-citationBrozanski, B. S., Jones, J., Gilmour, C., Balsan, M. J., Vazquez, R. L., Israel, B. A., Newman, B., Mimouni, F. B., & Guthrie, R. D. (1995) · The Journal of Pediatrics · doi:10.1016/s0022-3476(95)70410-8 · Cited by 121
Weichsel, M. E. (1977) · Annals of Neurology · doi:10.1002/ana.410020503 · Cited by 120
Clinical Trials of Postnatal Corticosteroids: Inhaled and Systemic
Halliday, H. L. (1999) · Neonatology · doi:10.1159/000047044 · Cited by 104
Self-citationDexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia.
Kari, M. A., Heinonen, K., Ikonen, R., Koivisto, M., & Raivio, K. O. (1993) · Archives of Disease in Childhood · doi:10.1136/adc.68.5_spec_no.566 · Cited by 89
Durand, M., Mendoza, M. E., Tantivit, P., Kugelman, A., & McEvoy, C. T. (2002) · PEDIATRICS · doi:10.1542/peds.109.2.262 · Cited by 73
Doyle, L. W., & Davis, P. G. (2000) · Journal of Paediatrics and Child Health · doi:10.1046/j.1440-1754.2000.00481.x · Cited by 69
Self-citationEarly (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants
Halliday, H. L., Ehrenkranz, R. A., & Doyle, L. W. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001146.pub3 · Cited by 66
Self-citationBloomfield, F. H., Knight, D. B., & Harding, J. E. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70277-x · Cited by 64
Surfactant phosphatidylcholine composition during dexamethasone treatment in chronic lung disease
Ashton, M. R., Postle, A. D., Smith, D. E., et al. (1994) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.71.2.f114 · Cited by 19
Cited by
Validation of the National Institutes of Health Consensus Definition of Bronchopulmonary Dysplasia
Ehrenkranz, R. A., Walsh, M. C., Vohr, B. R., Jobe, A. H., Wright, L. L., Fanaroff, A. A., Wrage, L. A., Poole, K., & for the National Institutes of Child Health and Human Development Neonatal Research Network (2005) · Pediatrics · doi:10.1542/peds.2005-0249 · Cited by 1,146
Self-citationOutcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of Prematurity
Yeh, T. F., Lin, Y. J., Lin, H. C., Huang, C. C., Hsieh, W. S., Lin, C. H., & Tsai, C. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032089 · Cited by 596
Cools, F., Offringa, M., & Askie, L. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000104.pub4 · Cited by 519
Dalziel, S. R., Walker, N. K., Parag, V., Mantell, C., Rea, H. H., Rodgers, A., & Harding, J. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66617-2 · Cited by 461
Barrington, K. J. (2001) · BMC Pediatrics · doi:10.1186/1471-2431-1-1 · Cited by 421
Metadata
- Authors
- Halliday, H. L., Ehrenkranz, R. A., & Doyle, L. W.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2003-01-20
- Volume
- 2011
- Issue
- 10
- Pages
- CD001144-CD001144
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1601301295
- Cited by
- 271
- References
- 19
- FWCI
- 18.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.